

[Review Form 3](#)

Book Name:	Achievements and Challenges of Medicine and Medical Science
Manuscript Number:	Ms_BPR_4098
Title of the Manuscript:	Tirosine kinase inhibitors (TKI) used in the treatment of non-small cell lung cancer (NSCLC) based on specific genetic alterations
Type of the Article	Book Chapter

PART 1: Comments

	Reviewer's comment	Author's Feedback <i>(Please correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Please write a few sentences regarding the importance of this manuscript for the scientific community. A minimum of 3-4 sentences may be required for this part.	This manuscript explains TKI therapy which is currently the treatment of choice for NSCLC with gene mutations. Recognizing type of TKI and its side effects is a very important first step in exploring lung cancer therapy which continues to develop. Simple and easy to understand explanations will help people who are just starting out, especially students, to learn this topic.	
Is the title of the article suitable? (If not please suggest an alternative title)	Yes it is suitable	
Is the abstract of the article comprehensive? Do you suggest the addition (or deletion) of some points in this section? Please write your suggestions here.	<p>I'm having trouble understanding the third sentence in the abstract. I think the wording could be improved a bit to make it easier for readers to understand..</p> <p>Perhaps it could be written with We also provide some remarks on Entrectinib, an NTRK fusion-specific TKI, for which molecular determination has been approved for reimbursement.</p> <p>In the keywords section, instead of "target therapy", it should be more understandable to write as "targeted therapy".</p>	
Is the manuscript scientifically, correct? Please write here.	<p>In section Osimertinib, First paragraph, last sentence. What are "mature OS were encouraging" referred to ? Perhaps the author could add some explanation about this Overall survival as what have been explained about PFS.</p> <p>Third paragraph, there is repetition of sentences. I suggest adding other region's policy about the drug like is it already approved in Europe or other region. This will give some useful information to reader</p> <p>fourth paragraph, last sentence. It would be better to be paraphrased. The current sentence seems to provide education about what will happen to the patient when taking the drug.</p> <p>Section Lazertinib First paragraph, last sentence. What does this sentence referred to ? I suggest adding some explanation about how the progression-free survival of Lazertinib compare to others.</p> <p>Second paragraph talks about lazertinib's side effect but the reference (9) is a journal about gefitinib, erlotinib and afatinib.</p> <p>Section Gefitinib, erlotinib, afatinib</p>	

Review Form 3

	<p>first paragraph, fourth sentence. Apamaksudnya ? I have difficulty understanding the meaning of that sentence. What does the author mean by "in the some percent and have the some result" ?</p> <p>For the eighth and ninth sentence, it would be better to add some explanation which meta-analysis that the author referenced.</p> <p>In section Dacomitinib In the last sentence. What is meant by ETR? It would be better to add some explanation to avoid confusion</p>	
Are the references sufficient and recent? If you have suggestions of additional references, please mention them in the review form.	The references should be written based on vancouver citation style.	
Is the language/English quality of the article suitable for scholarly communications?	There are some confusing sentences. I think the author should correct some ambiguous sentences by paraphrasing.	
Optional/General comments		

PART 2:

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	Ni Nyoman Widyastuti Lestari
Department, University & Country	Parama Sidhi Hospital, Indonesia